Diamyd Medical receives increased patent protection
Diamyd Medical today announced that the U.S. Patent Attorney at the University of California, Los Angeles, (UCLA), has informed that another Diamyd Medical licensed UCLA patent application will be granted. The patent includes protection for treating type 1 diabetes with the combination GABA and the diabetes vaccine Diamyd® and has a maturity until September 27, 2031. Previously, a patent within the same patent family has been granted covering diabetes treatment with GABA and preproinsulin or an immunogenic fragment thereof.Diamyd Medical has previously licensed several approved independent